A multicentre, randomised, double-blind, placebo- and active-controlled phase I trial to evaluate the safety and efficacy of olanzapine/samidorphan in the prevention of olanzapine-induced weight gain in healthy male volunteers

Trial Profile

A multicentre, randomised, double-blind, placebo- and active-controlled phase I trial to evaluate the safety and efficacy of olanzapine/samidorphan in the prevention of olanzapine-induced weight gain in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 May 2013

At a glance

  • Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 May 2013 Results published in an Alkermes plc media release.
    • 22 May 2013 Data will be presented at the 53rd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, according to an Alkermes plc media release.
    • 10 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top